134 related articles for article (PubMed ID: 22074578)
1. Pituitary microadenoma treated with antipsychotic drug aripiprazole.
Wix-Ramos RJ; Paez R; Capote E; Ezequiel U
Recent Pat Endocr Metab Immune Drug Discov; 2011 Jan; 5(1):58-60. PubMed ID: 22074578
[TBL] [Abstract][Full Text] [Related]
2. Treatment with aripiprazole for hyperprolactinemia induced by pituitary microadenoma in a bipolar I disorder patient.
Chen ST; Hsiao YL
J Clin Psychopharmacol; 2010 Feb; 30(1):78-80. PubMed ID: 20075655
[No Abstract] [Full Text] [Related]
3. Treatment of antipsychotic-induced hyperprolactinemia: an update on the role of the dopaminergic receptors D2 partial agonist aripiprazole.
De Berardis D; Fornaro M; Serroni N; Marini S; Piersanti M; Cavuto M; Valchera A; Mazza M; Girinelli G; Iasevoli F; Perna G; Martinotti G; Di Giannantonio M
Recent Pat Endocr Metab Immune Drug Discov; 2014 Jan; 8(1):30-7. PubMed ID: 24372345
[TBL] [Abstract][Full Text] [Related]
4. The effect of aripiprazole and quinagolide, a dopamine agonist, in a patient with symptomatic pituitary prolactinoma and chronic psychosis.
Broekhof R; Gosselink MJ; Pijl H; Giltay EJ
Gen Hosp Psychiatry; 2012; 34(2):209.e1-3. PubMed ID: 21872335
[TBL] [Abstract][Full Text] [Related]
5. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
Shim JC; Shin JG; Kelly DL; Jung DU; Seo YS; Liu KH; Shon JH; Conley RR
Am J Psychiatry; 2007 Sep; 164(9):1404-10. PubMed ID: 17728426
[TBL] [Abstract][Full Text] [Related]
6. Aripiprazole: what is the role of dopamine D(2) receptor partial agonism?
Kessler RM
Am J Psychiatry; 2007 Sep; 164(9):1310-2. PubMed ID: 17728411
[No Abstract] [Full Text] [Related]
7. Evidence for the partial dopamine-receptor agonist aripiprazole as a first-line treatment of psychosis in patients with iatrogenic or tumorogenic hyperprolactinemia.
Hoffer ZS; Roth RL; Mathews M
Psychosomatics; 2009; 50(4):317-24. PubMed ID: 19687170
[TBL] [Abstract][Full Text] [Related]
8. Successful use of aripiprazole for delusional disorder with comorbid pituitary microadenoma: a case report.
Jayaram N; Rao NP; Venkatasubramanian G; Behere RV; Varambally S; Gangadhar BN
Psychosomatics; 2011; 52(4):395-7. PubMed ID: 21777728
[No Abstract] [Full Text] [Related]
9. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
Swainston Harrison T; Perry CM
Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
[TBL] [Abstract][Full Text] [Related]
10. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic.
Keck PE; McElroy SL
Expert Opin Investig Drugs; 2003 Apr; 12(4):655-62. PubMed ID: 12665420
[TBL] [Abstract][Full Text] [Related]
11. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
[TBL] [Abstract][Full Text] [Related]
12. Normalization of prolactin with aripiprazole in a patient with psychotic depression and a comorbid pituitary microadenoma.
Steinhagen CK
Psychosomatics; 2007; 48(4):350-1. PubMed ID: 17600173
[No Abstract] [Full Text] [Related]
13. Hyperprolactinemia Secondary to Pituitary Microadenoma Versus Haloperidol- A Diagnostic Enigma. A Case Report and Brief Review.
Madhusoodanan S; Steinberg LR; Coleman A; Bavli S
Curr Drug Saf; 2017; 12(1):19-21. PubMed ID: 27440143
[TBL] [Abstract][Full Text] [Related]
14. Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience.
Fernandez HH; Trieschmann ME; Friedman JH
Clin Neuropharmacol; 2004; 27(1):4-5. PubMed ID: 15090928
[TBL] [Abstract][Full Text] [Related]
15. Successful monotherapy treatment with aripiprazole in a patient with schizophrenia and prolactinoma.
Freeman B; Levy W; Gorman JM
J Psychiatr Pract; 2007 Mar; 13(2):120-4. PubMed ID: 17414690
[No Abstract] [Full Text] [Related]
16. Aripiprazole in psychosis associated with Parkinson's disease.
López-Meza E; Ruiz-Chow A; Ramirez-Bermudez J
J Neuropsychiatry Clin Neurosci; 2005; 17(3):421-2. PubMed ID: 16179668
[TBL] [Abstract][Full Text] [Related]
17. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
Lu ML; Shen WW; Chen CH
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
[TBL] [Abstract][Full Text] [Related]
18. Differential effects on D2 dopamine receptor and prolactin gene expression by haloperidol and aripiprazole in the rat pituitary.
Inoue A; Seto M; Sugita S; Hide I; Hirose T; Koga N; Kikuchi T; Nakata Y
Brain Res Mol Brain Res; 1998 Apr; 55(2):285-92. PubMed ID: 9582438
[TBL] [Abstract][Full Text] [Related]
19. Aripiprazole and haloperidol: beneficial combination antipsychotic therapy for a schizophrenic patient.
Kuo J; Hwu HG
Clin Neuropharmacol; 2008; 31(3):173-5. PubMed ID: 18520984
[TBL] [Abstract][Full Text] [Related]
20. Aripiprazole alone or in combination for acute mania.
Brown R; Taylor MJ; Geddes J
Cochrane Database Syst Rev; 2013 Dec; (12):CD005000. PubMed ID: 24346956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
